strong revenu growth deliv across product line geographi
reiter market outperform rate rais price target
follow releas result
particularli impress quarter organ cc growth acceler significantli
double-digit rang ex impact one fewer sell day
y/i importantli strength broad base geograph division
standpoint urolift trend remain excel y/i core legaci
busi contribut solid mid-single-digit advanc well fact top-lin
upsid prompt compani rais sale growth forecast
new midpoint compris urolift line
indic manag confid sustain base trajectori
new price target base pe prior appli
ep estim repres slight premium group
med-tech peer consist high top- bottom-lin growth profil
believ share continu appreci consid compani
revenu growth opportun featur organ acceler
cc growth perhap look like higher end rang
achiev manag secular effort improv profit restructur
initi manufactur excel program strong track record
strateg acquir net leverag support anoth scale
transact essenti compani emerg large-cap play better
prospect time recal within last decad
cover name
deliv top- bottom-lin upsid total sale
mln y/i cc ex sell day impact handili exceed
street mln estim upsid adjust ep
y/i cc compar consensu beat
given strength manag rais target cc revenu growth
reiter adjust ep rang reflect
increment fx headwind invest pipelin
diversifi posit result visibl across oper segment
notabl cc perform vascular access y/i intervent
y/i intervent urolog y/i surgic y/i oem
y/i busi far compani geograph breakdown cc
growth led sale america saw sizabl increas
within intervent urolog surgic vascular access product asia
y/i driven strength china korea southeast
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
turn tfx key financi metric gross margin came bp y/i
adjust oper margin bp y/i gross margin expans reflect
benefit elev sale volum cost improv program favor sale mix
higher-margin product posit partial off-set neg impact fx
increment tariff well higher logist distribut cost beyond fx headwind
differ y/i chang gross oper margin bp versu bp
respect explain addit sell expens relat revenu upsid
select invest currenc neutral basi adjust oper margin second
quarter would flat y/i manag reiter full-year gross margin guidanc
bp y/i slightli lower oper margin expect bp
midpoint due increas headwind fx
manag also made slight alter full-year guidanc updat top-lin
margin expect mention result reiter adjust ep
y/i sale growth guidanc rais y/i
previous constant currenc revenu y/i previous
cc note manag comment approxim one-third sale rais driven
expect urolift growth y/i versu rest tfx product account
remaind increas higher fx impact previous adjust
ep expect off-set continu strength compani revenu growth
compani also gave addit commentari recent clinic reimburs updat
urolift product note manag announc revis surgic minim
invas bph polici includ urolift product achiev coverag
nation region commerci plan independ license bcb well medicar
addit impress mileston compani also announc public
patient real-world studi quarter result consist urolift prior
pivot studi demonstr product efficaci safeti treat bph
manag made adjust guidanc sale growth margin ep
reiter figur highlight key guidanc metric along chang select commentari
figur follow page highlight result rang revenu metric along
select commentari compani recent chang report segment therefor estim
align report result
rang bln expect bp headwind foreign exchang revenu rais driven urolift driven remaind product rais due better-than-expect revenu perform full-year urolift revenu growth guidanc rais gross intervent urolog intervent access product mix expect continu benefit manufactur product improv program previous announc restructur programsoper margin ex lower due increas headwind fx addit sell expens associ revenu out-performance urolift area busi proactiv invest design enhanc futur growth prospect includ upgrad qualiti system strengthen ip expect low end rang adj fx assumpt full year headwind versu previou expect abl maintain earn guidanc despit increas headwind fx due expect strength revenu teleflex incorpor
 edeltacommentsvascular bpsintervent bpsintervent bpstotal mlnannual bpsgross bp bp y/i expans primarili reflect increas sale volum benefit cost improv fx increment tariff higher logisitc distributioncost bpsoper bpsdown bp y/i improv gross margin off-set neg impact fx addit sell expens relat revenu upsid qualiti system upgrad currenc neutral basi adjust oper margin would approxim flat tax bpsnet bpsadjust cc driven increas sale bladder manag product off-set declin sale respiratori cc strong growth cvc picc ez-io saw increas distributor order esenti versu destock neg impact cc broad-bas performc growth complex cathert biolog oncontrol intra-aort balloon product first month manta limit marker releas posit manta expect contribut top-lin result cc declin primarili driven soft airway pain manag product cc driven sale ligat clip surgic cc sale growth expect approx previous forc continu progress drive physician adopt urolift expect train total urologist continu expect roll-out urolift latter half year full convers us physician base expect track limit market releas japan mid-to late- cc growth led strength sutur cathet product offer upper singl digit growth still expect teleflex incorpor
pure-play med-tech compani transform via merger acquisit number year industri
conglomer foray medic devic industri began late compani began use polym technolog
manufactur intraven cathet tube ultim sold oem grew medic segment late
acquisit rusch pill weck creat medic busi includ dispos
reusabl devic latex cathet endotrach tube laryngoscop face mask tracheotomi tube urolog
gastroenterolog anesthesiolog market well ligat gener surgic devic transform divest
non-med asset make number mostli bolt-on acquisit cap substanti bln purchas
late compani also purchas lma mln vidacar mln
invest thesi valuat subject number risk oper highli competit medic devic market character
price pressur ip disput medic devic highli regul compani fail fda inspect could receiv
warn letter potenti lose abil sell certain product company-specif front reli acquisit bolster
growth profil increas invest guarante acquisit pipelin product accret valu
compani abl execut oper effici program
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign david turkali daniel stauder
jmp secur current make market secur teleflex incorpor
market outperform mo jmp secur expect stock price outperform relev market indic next month
market perform mp jmp secur expect stock price perform line relev market indic next month
market under-perform mu jmp secur expect stock price under-perform relev market indic next month
jmp secur research rate invest bank servic august
co
servic
stock price chart rate price chang
note first annot denot initi coverag year whichev shorter target price list target price n/a
accord finra rule chart reflect price rang chang rate price target end
recent calendar quarter action reflect note annot stock price chart jmp secur
jmp secur llc firm compens research analyst like firm employe base firm profit includ
revenu firm institut sale trade invest bank depart well qualiti servic activ
perform intend benefit firm institut client data prepar jmp secur llc inform
purpos base inform avail public sourc believ reliabl guarante
accuraci complet opinion project express herein reflect judgment date subject chang
without notic data neither intend consid offer sell solicit basi contract
purchas secur financi product jmp secur llc affili jmp group llc harvest capit strategi llc
respect partner director offic associ may long short posit may act market maker may
purchas sell posit secur mention herein jmp secur llc affili may perform perform seek
perform invest bank advisori servic may act manag co-manag public offer secur
compani mention herein reader assum jmp secur llc solicit busi compani cover
report member sale trade depart provid oral and/or written market opinion trade strategi client
reflect person opinion stock subject firm research report research analyst discuss trade
strategi client sometim reflect short-term expect price secur subject research report
trade strategi distinct analyst fundament rate stock base upon analyst view compar
stock coverag relev time period copyright right reserv jmp secur llc jmp secur
llc member finra sipc
director research
director equiti
director sale trade
